Article
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
Blood - 15 May 2008
Haberichter Sandra L, Castaman Giancarlo, Budde Ulrich, Peake Ian, Goodeve Anne, Rodeghiero Francesco, Federici Augusto B, Batlle Javier, Meyer Dominique, Mazurier Claudine, Goudemand Jenny, Eikenboom Jeroen, Schneppenheim Reinhard, Ingerslev Jorgen, Vorlova Zdena, Habart David, Holmberg Lars, Lethagen Stefan, Pasi John, Hill Frank G H, Montgomery Robert R
Abstract excerpt
The decreased survival of von Willebrand factor (VWF) in plasma has been implicated as a mechanism in a subset of type 1 von Willebrand disease (VWD) patients. We have previously reported that the ratio of plasma levels of VWF and its propeptide (VWFpp) can be used to identify patients with reduced VWF survival. In this study, we report the assay of VWFpp and VWF:Ag in 19 individuals recruited from 6 European...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.